Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

This study has been completed.
Sponsor:
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002064
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: June 1989

November 2, 1999
June 23, 2005
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00002064 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse
Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.

Not Provided
Interventional
Not Provided
Primary Purpose: Treatment
  • Toxoplasmosis, Cerebral
  • HIV Infections
  • Drug: Pyrimethamine
  • Drug: Clindamycin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions are excluded:

  • Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis) or other conditions (brain abscess) which would make treatment results difficult to interpret due to concurrent infection, disease, or therapy.

Patients with other opportunistic infections or brain diseases are excluded.

Patients with AIDS and cerebral toxoplasmosis.

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00002064
021A
Not Provided
Not Provided
Palo Alto Medical Foundation
Not Provided
Not Provided
NIH AIDS Clinical Trials Information Service
June 1989

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP